Estate of Robert W. Petersen, by and through Robert T. Petersen as Personal Representative; Estate of Mary Ann Simons, by and through Dean Simons as Personal Representative; and Estate of Charlotte Elaine Guilford, by and through Charles Guilford as Personal Representative v. Koelsch Senior Communities, LLC and Billings Partners, LLC d/b/a Canyon Creek

Summary

The United States District Court for the District of Montana ruled on Defendants’ Motions in Limine Nos. 1-10 in a negligence action arising from alleged failures to care for residents during a COVID-19 outbreak at a memory care and assisted living facility. The court denied or deferred several broad evidentiary requests but granted motions concerning ultimate-issue questions, discovery disputes, witness credibility commentary, hindsight testimony, untimely documents, and medical treatise requirements. The case involves the estates of Robert W. Petersen, Mary Ann Simons, and Charlotte Elaine Guilford against Koelsch Senior Communities, LLC and Billings Partners, LLC.

Holdings

1. A motion in limine should not be used to resolve factual disputes, weigh evidence, or exclude broad categories of evidence when admissibility depends on trial context; evidence should be excluded pretrial only when it is inadmissible on all potential grounds.
2. Lay witnesses may testify about personal observations, including observations pertaining to medical matters, when the testimony is rationally based on their own perception; they may not offer expert testimony, including testimony on causation.
3. A plaintiff may pursue reimbursement fees when the amount can be reasonably approximated, even if the damages request was broadly stated or originally included amounts no longer sought; the plaintiff retains the burden to prove the fees at trial.
4. A motion in limine is not the proper vehicle to obtain a ruling that a loss-of-consortium claim is unavailable or inadequately pleaded; such issues should be raised through a motion to dismiss or summary judgment.
5. A witness's title alone does not establish that the witness is a director under Federal Rule of Civil Procedure 32; deposition testimony may be used for any purpose against an organizational party only when the witness is an adverse party, an officer, director, managing agent, or Rule 30(b)(6) designee, or when another applicable Rule 32 condition such as unavailability is satisfied.
6. A witness may not testify about the credibility of another witness because credibility determinations are for the jury, although counsel may address credibility during cross-examination.
7. Policies, standards, guidelines, procedures, and marketing materials not in effect during the periods relevant to the alleged incidents are inadmissible at trial; an undated document may be admitted only if its proponent lays a foundation showing that it was in effect during the relevant period.
8. Plaintiffs may not elicit irrelevant hindsight testimony that would not assist the jury in evaluating the applicable standard of care and could mislead the jury.
9. Medical treatises and journals may be used only in accordance with Federal Rule of Evidence 803(18), and the court will apply the Rules of Evidence at trial rather than make a broader pretrial ruling.

Questions Presented

1. Whether the challenged categories of lay-witness testimony, damages evidence, opening-statement argument, deposition testimony, discovery-dispute references, credibility testimony, later-created documents, hindsight testimony, and medical literature should be excluded or limited before trial.
2. Whether lay witnesses may testify about personal observations, including observations concerning medical conditions and care, while being barred from offering expert testimony such as causation opinions.
3. Whether the deposition of a witness may be used against an organizational party for any purpose under Federal Rule of Civil Procedure 32 when the witness's title alone does not establish that the witness was an officer, director, managing agent, or Rule 30(b)(6) designee.
4. Whether evidence concerning loss-of-consortium damages and reimbursement fees should be excluded based on pleading or damages-disclosure arguments.
5. Whether evidence and argument concerning documents not in effect during the relevant period, hindsight testimony, credibility opinions, discovery disputes, and medical treatises should be excluded or controlled at trial.

Disposition

other